Artiva slumps premarket after discontinuing lead asset AlloNK
FROM THE WIRE · SEEKINGALPHA.COM
[Loss In American Dollar] MicroStockHub Artiva Biotherapeutics (ARTV [https://seekingalpha.com/symbol/ARTV]) lost more than 30% in premarket trading on Tuesday after the cell therapy developer laid off nearly 94% of its staff amid plans to discontinue further studies into its…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishSharp drop in a small biotech after trial deaths and layoffs of nearly 94% of staff.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Artiva lost more than 30% in premarket trading on Tuesday.
- 02Two Grade 5 adverse events in the Phase 2a trial resulted in deaths.
- 03The company laid off nearly 94% of staff and plans to discontinue AlloNK.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets